目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 36)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 CAR T-CELL THERAPY MARKET SEGMENTATION
1.3.2 REGIONS COVERED
FIGURE 2 CAR T-CELL THERAPY MARKET: REGIONAL SEGMENTATION
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 40)
2.1 RESEARCH DATA
FIGURE 3 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.3 BREAKDOWN OF PRIMARIES
FIGURE 4 BREAKDOWN OF PRIMARIES: CAR T-CELL THERAPY MARKET
2.2 MARKET SIZE ESTIMATION
FIGURE 5 CAR T-CELL THERAPY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
FIGURE 6 CAR T-CELL THERAPY MARKET SIZE ESTIMATION (PRODUCT-BASED ANALYSIS), 2023
FIGURE 7 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (PRODUCTS), 2023
FIGURE 8 ILLUSTRATIVE EXAMPLE OF GILEAD SCIENCES, INC.: REVENUE SHARE ANALYSIS (2023)
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 9 MARKET VALIDATION FROM PRIMARY SOURCES
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION
FIGURE 10 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH RATE ASSUMPTIONS
2.3.1 CAGR PROJECTIONS
FIGURE 11 CAR T-CELL THERAPY MARKET: CAGR PROJECTIONS, 2024-2029
2.3.2 IMPACT OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
2.4 VOLUME ESTIMATION
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 12 DATA TRIANGULATION METHODOLOGY
2.6 RESEARCH LIMITATIONS
2.7 STUDY ASSUMPTIONS
2.8 RISK ANALYSIS
2.9 RECESSION IMPACT ANALYSIS
TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2023-2029 (% GROWTH)

3 EXECUTIVE SUMMARY (Page No. - 53)
FIGURE 13 CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024 VS 2029 (USD MILLION)
FIGURE 14 CAR T-CELL THERAPY MARKET, BY TARGET, 2024 VS. 2029 (USD MILLION)
FIGURE 15 CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024 VS. 2029 (USD MILLION)
FIGURE 16 CAR T-CELL THERAPY MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 17 CAR T-CELL THERAPY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 18 GEOGRAPHICAL SNAPSHOT OF CAR T-CELL THERAPY MARKET

4 PREMIUM INSIGHTS (Page No. - 57)
4.1 CAR T-CELL THERAPY MARKET OVERVIEW
FIGURE 19 GROWING PREVALENCE OF CANCER TO DRIVE MARKET
4.2 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT AND COUNTRY (2023)
FIGURE 20 US AND YESCARTA COMMANDED LARGEST SHARE IN NORTH AMERICAN CAR T-CELL THERAPY MARKET IN 2023
4.3 CAR T-CELL THERAPY MARKET SHARE, BY PRODUCT
FIGURE 21 YESCARTA HELD HIGHEST GLOBAL MARKET SHARE IN 2023
4.4 CAR T-CELL THERAPY MARKET, BY END USER
FIGURE 22 HOSPITALS SEGMENT TO GROW AT HIGHEST CAGR DURING STUDY PERIOD

5 MARKET OVERVIEW (Page No. - 60)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 23 CAR T-CELL THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing cancer prevalence
5.2.1.2 Technological advancements in CAR T-cell therapies
5.2.1.3 Rising investment and funding for therapy development
5.2.2 RESTRAINTS
5.2.2.1 High therapy costs
5.2.2.2 Adverse effects
TABLE 3 ADVERSE EFFECTS ASSOCIATED WITH CAR T-CELL THERAPY
5.2.3 OPPORTUNITIES
5.2.3.1 Expansion into solid tumors
5.2.3.2 Collaborations and partnerships
5.2.4 CHALLENGES
5.2.4.1 Patient recruitment for trials
5.2.4.2 Reimbursement issues
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 24 REVENUE SHIFT IN CAR T-CELL THERAPY MARKET
5.4 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS: CAR T-CELL THERAPY PRODUCTS
5.5 ECOSYSTEM ANALYSIS
FIGURE 26 CAR T-CELL THERAPY MARKET: ECOSYSTEM
5.5.1 PRODUCTS
TABLE 4 KEY PRODUCT PROVIDERS IN CAR T-CELL THERAPY MARKET
5.5.2 END USERS
TABLE 5 KEY END USERS IN CAR T-CELL THERAPY MARKET
5.5.3 REGULATORY BODIES
TABLE 6 KEY REGULATORY BODIES IN CAR T-CELL THERAPY MARKET
5.6 TECHNOLOGY ANALYSIS
5.6.1 KEY TECHNOLOGIES
5.6.1.1 CAR DESIGN AND OPTIMIZATION
5.6.1.2 VIRAL VECTOR TECHNOLOGY
5.6.1.3 CELL CULTURE AND EXPANSION TECHNIQUES
5.6.2 COMPLIMENTARY TECHNOLOGIES
5.6.2.1 GENE EDITING TECHNOLOGY (CRISPR-CAS9-BASED GENOME EDITING)
5.6.3 ADJACENT TECHNOLOGIES
5.6.3.1 MONITORING AND IMAGING TECHNOLOGIES
5.7 PATENT ANALYSIS
5.7.1 METHODOLOGY
5.7.2 NUMBER OF PATENTS FILED
TABLE 7 NUMBER OF PATENTS FILED IN CAR T-CELL THERAPY MARKET, BY DOCUMENT TYPE, 2014-2024
5.7.3 INNOVATION AND PATENT APPLICATIONS
FIGURE 27 TOTAL NUMBER OF PATENTS GRANTED IN CAR T-CELL THERAPY MARKET, 2014-2023
5.7.4 TOP APPLICANTS
FIGURE 28 TOP 13 PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014-2024
FIGURE 29 REGIONAL ANALYSIS OF PATENTS GRANTED, 2014-2024
TABLE 8 TOP 12 PATENT OWNERS IN CAR T-CELL THERAPY MARKET, 2014-2024
TABLE 9 DETAILED ANALYSIS OF KEY PATENTS IN CAR T-CELL THERAPY MARKET
5.8 PRICING ANALYSIS
5.8.1 AVERAGE SELLING PRICE, BY TYPE
TABLE 10 AVERAGE SELLING PRICE FOR LEADING CAR T-CELL THERAPEUTIC DRUGS
5.8.2 AVERAGE SELLING PRICE, BY REGION
TABLE 11 AVERAGE SELLING PRICE FOR MAJOR CAR T-CELL THERAPEUTIC DRUGS, BY REGION
5.8.3 AVERAGE SELLING PRICE TREND, BY PRODUCT
TABLE 12 INDICATIVE PRICING ANALYSIS FOR CAR T-CELL THERAPY, BY PRODUCT, 2021-2023
5.9 KEY CONFERENCES & EVENTS, 2024-2O25
TABLE 13 KEY CONFERENCES & EVENTS, JUNE 2024-DECEMBER 2025
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY SCENARIO
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 INVESTMENT & FUNDING SCENARIO
5.12 PORTER’S FIVE FORCES ANALYSIS
FIGURE 30 CAR T-CELL THERAPY MARKET
TABLE 19 CAR T-CELL THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.12.1 INTENSITY OF COMPETITIVE RIVALRY
5.12.2 BARGAINING POWER OF SUPPLIERS
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 THREAT OF SUBSTITUTES
5.12.5 THREAT OF NEW ENTRANTS
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
FIGURE 31 KEY STAKEHOLDERS IN PRODUCT BUYING PROCESS
TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
5.13.1 KEY BUYING CRITERIA
FIGURE 32 KEY BUYING CRITERIA FOR PRODUCTS
TABLE 21 KEY BUYING CRITERIA FOR PRODUCTS

6 CAR T-CELL THERAPY MARKET, BY PRODUCT (Page No. - 97)
6.1 INTRODUCTION
TABLE 22 CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 23 CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (UNITS)
6.2 YESCARTA
6.2.1 INCREASING REACH TO DRIVE MARKET
TABLE 24 YESCARTA MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 25 NORTH AMERICA: YESCARTA MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 26 EUROPE: YESCARTA MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC: YESCARTA MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 28 LATIN AMERICA: YESCARTA MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
6.3 KYMRIAH
6.3.1 APPROVAL FOR PEDIATRIC USE TO SUPPORT MARKET GROWTH
TABLE 29 KYMRIAH MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 30 NORTH AMERICA: KYMRIAH MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 31 EUROPE: KYMRIAH MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC: KYMRIAH MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 33 LATIN AMERICA: KYMRIAH MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
6.4 CARVYKTI
6.4.1 WIDESPREAD REACH TO ENSURE MARKET GROWTH
TABLE 34 CARVYKTI MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 35 NORTH AMERICA: CARVYKTI MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 36 EUROPE: CARVYKTI MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 37 ASIA PACIFIC: CARVYKTI MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 38 LATIN AMERICA: CARVYKTI MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
6.5 ABECMA
6.5.1 RISING RESEARCH FOR ALTERNATIVE INDICATIONS TO DRIVE MARKET
TABLE 39 ABECMA MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 40 NORTH AMERICA: ABECMA MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 41 EUROPE: ABECMA MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 42 ASIA PACIFIC: ABECMA MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 43 LATIN AMERICA: ABECMA MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
6.6 TECARTUS
6.6.1 GROWING FOCUS ON PATIENT-CENTRIC REIMBURSEMENT TO PROPEL MARKET
TABLE 44 TECARTUS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 45 NORTH AMERICA: TECARTUS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 46 EUROPE: TECARTUS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 47 ASIA PACIFIC: TECARTUS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 48 LATIN AMERICA: TECARTUS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
6.7 BREYANZI
6.7.1 MULTIPLE INDICATIONS TO PROPEL MARKET GROWTH
TABLE 49 BREYANZI MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 50 NORTH AMERICA: BREYANZI MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 51 EUROPE: BREYANZI MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 52 ASIA PACIFIC: BREYANZI MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 53 LATIN AMERICA: BREYANZI MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
6.8 OTHER PRODUCTS
TABLE 54 OTHER CAR T-CELL THERAPY PRODUCTS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 55 NORTH AMERICA: OTHER CAR T-CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 56 EUROPE: OTHER CAR T-CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 57 ASIA PACIFIC: OTHER CAR T-CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 58 LATIN AMERICA: OTHER CAR T-CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)

7 CAR T-CELL THERAPY MARKET, BY TARGET (Page No. - 117)
7.1 INTRODUCTION
TABLE 59 CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
7.2 CD19
7.2.1 RISING INDICATIONS IN PIPELINE TO DRIVE MARKET
TABLE 60 COMMERCIALLY AVAILABLE CD19 ANTIGEN-TARGETING CAR T-CELL THERAPIES
TABLE 61 CD19-TARGETING CAR T-CELL THERAPY MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 62 NORTH AMERICA: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 63 EUROPE: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 64 ASIA PACIFIC: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 65 LATIN AMERICA: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
7.3 BCMA
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN CAR T-CELL THERAPY TO PROPEL MARKET GROWTH
TABLE 66 COMMERCIALLY AVAILABLE BCMA ANTIGEN-TARGETING CAR T-CELL THERAPIES
TABLE 67 BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 68 NORTH AMERICA: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 69 EUROPE: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 70 ASIA PACIFIC: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 71 LATIN AMERICA: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
7.4 OTHER TARGETS
TABLE 72 OTHER CAR T-CELL THERAPY TARGETS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 73 NORTH AMERICA: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 74 EUROPE: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 75 ASIA PACIFIC: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 76 LATIN AMERICA: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)

8 CAR T-CELL THERAPY MARKET, BY INDICATION (Page No. - 128)
8.1 INTRODUCTION
TABLE 77 CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
8.2 MULTIPLE MYELOMA
8.2.1 RISING INCIDENCE OF MULTIPLE MYELOMA TO DRIVE MARKET
TABLE 78 MULTIPLE MYELOMA, BY REGION, 2022-2029 (USD MILLION)
TABLE 79 NORTH AMERICA: MULTIPLE MYELOMA MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 80 EUROPE: MULTIPLE MYELOMA MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 81 ASIA PACIFIC: MULTIPLE MYELOMA MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 82 LATIN AMERICA: MULTIPLE MYELOMA MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
8.3 B-CELL LYMPHOMA
8.3.1 RISING PREVALENCE TO PROPEL MARKET GROWTH
TABLE 83 CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA, BY REGION, 2022-2029 (USD MILLION)
TABLE 84 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 85 EUROPE: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 86 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 87 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
8.4 ACUTE LYMPHOBLASTIC LEUKEMIA
8.4.1 FOCUS ON AFFORDABLE CAR T-CELL THERAPIES TO DRIVE MARKET
TABLE 88 CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2022-2029 (USD MILLION)
TABLE 89 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 90 EUROPE: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 91 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 92 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
8.5 OTHER INDICATIONS
TABLE 93 CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY REGION, 2022-2029 (USD MILLION)
TABLE 94 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 95 EUROPE: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 96 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 97 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)

9 CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC (Page No. - 141)
9.1 INTRODUCTION
TABLE 98 CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
9.2 ADULTS
9.2.1 INCREASING NUMBER OF LYMPHOMAS TO DRIVE MARKET
TABLE 99 CAR T-CELL THERAPY MARKET FOR ADULTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 100 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 101 EUROPE: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 102 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 103 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY, 2022-2029 (USD MILLION)
9.3 PEDIATRICS
9.3.1 RISING PREVALENCE OF TARGET DISEASES TO PROPEL MARKET GROWTH
TABLE 104 CAR T-CELL THERAPY MARKET FOR PEDIATRICS, BY REGION, 2022-2029 (USD MILLION)
TABLE 105 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR PEDIATRICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 106 EUROPE: CAR T-CELL THERAPY MARKET FOR PEDIATRICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 107 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR PEDIATRICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 108 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR PEDIATRICS, BY COUNTRY, 2022-2029 (USD MILLION)

10 CAR T-CELL THERAPY MARKET, BY END USER (Page No. - 148)
10.1 INTRODUCTION
TABLE 109 CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
10.2 HOSPITALS
10.2.1 GROWING PREVALENCE OF CANCER TO DRIVE MARKET
TABLE 110 CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)
TABLE 111 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 112 EUROPE: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 113 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 114 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
10.3 SPECIALTY CENTERS
10.3.1 GROWING RESEARCH COLLABORATIONS TO PROPEL MARKET
TABLE 115 CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 116 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 117 EUROPE: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 118 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 119 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
10.4 LONG-TERM CARE FACILITIES
10.4.1 GROWING CASES OF CHRONIC DISORDERS TO DRIVE MARKET
TABLE 120 CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 121 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 122 EUROPE: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 123 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 124 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)

11 CAR T-CELL THERAPY MARKET, BY REGION (Page No. - 157)
11.1 INTRODUCTION
TABLE 125 CAR T-CELL THERAPY MARKET, BY REGION, 2022-2029 (USD MILLION)
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 33 NORTH AMERICA: CAR T-CELL THERAPY MARKET SNAPSHOT
TABLE 126 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 127 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 128 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 129 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 130 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 131 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.2.2 US
11.2.2.1 Rising R&D activities for CAR T-cell therapies to drive market
TABLE 132 US: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 133 US: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 134 US: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 135 US: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 136 US: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Government initiatives for regenerative medicine research to drive market
TABLE 137 CANADA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 138 CANADA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 139 CANADA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 140 CANADA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 141 CANADA: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
TABLE 142 EUROPE: CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 143 EUROPE: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 144 EUROPE: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 145 EUROPE: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 146 EUROPE: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 147 EUROPE: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.2 GERMANY
11.3.2.1 Rising focus on clinical research to drive market
TABLE 148 GERMANY: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 149 GERMANY: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 150 GERMANY: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 151 GERMANY: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 152 GERMANY: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.3 UK
11.3.3.1 Rising technological advancements in automation to drive market
TABLE 153 UK: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 154 UK: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 155 UK: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 156 UK: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 157 UK: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Growing focus on cell & gene therapy initiatives to boost demand
TABLE 158 FRANCE: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 159 FRANCE: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 160 FRANCE: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 161 FRANCE: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 162 FRANCE: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.5 ITALY
11.3.5.1 Growth in biotech sector to drive market
TABLE 163 ITALY: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 164 ITALY: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 165 ITALY: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 166 ITALY: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 167 ITALY: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Rising focus on cell therapies to support market growth
TABLE 168 SPAIN: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 169 SPAIN: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 170 SPAIN: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 171 SPAIN: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 172 SPAIN: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 173 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 174 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 175 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 176 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 177 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 34 ASIA PACIFIC: CAR T-CELL THERAPY MARKET SNAPSHOT
TABLE 178 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 179 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 180 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 181 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 182 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 183 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Rising number of CAR T-cell clinical trials to support market growth
TABLE 184 CHINA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 185 CHINA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 186 CHINA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 187 CHINA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 188 CHINA: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4.3 JAPAN
11.4.3.1 Increasing product approvals to drive market
TABLE 189 JAPAN: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 190 JAPAN: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 191 JAPAN: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 192 JAPAN: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 193 JAPAN: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4.4 INDIA
11.4.4.1 Rising incidence of cancer and growing focus on product commercialization to boost demand
TABLE 194 INDIA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 195 INDIA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 196 INDIA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 197 INDIA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 198 INDIA: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4.5 AUSTRALIA
11.4.5.1 Robust infrastructure for clinical trials and well-developed healthcare sector to drive market
TABLE 199 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 200 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 201 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 202 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 203 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4.6 SOUTH KOREA
11.4.6.1 Rising growth in biopharmaceutical industry to drive market
TABLE 204 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 205 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 206 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 207 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 208 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4.7 REST OF ASIA PACIFIC
TABLE 209 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 210 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 211 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 212 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 213 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 214 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 215 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 216 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 217 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 218 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 219 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.5.2 BRAZIL
11.5.2.1 High expenditure on healthcare to support market growth
TABLE 220 BRAZIL: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 221 BRAZIL: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 222 BRAZIL: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 223 BRAZIL: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 224 BRAZIL: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.5.3 REST OF LATIN AMERICA
TABLE 225 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 226 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 227 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 228 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 229 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 MEA TO GROW AT SLOWER PACE DURING FORECAST PERIOD
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 230 MIDDLE EAST & AFRICA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 231 MIDDLE EAST & AFRICA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022-2029 (USD MILLION)
TABLE 232 MIDDLE EAST & AFRICA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
TABLE 233 MIDDLE EAST & AFRICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022-2029 (USD MILLION)
TABLE 234 MIDDLE EAST & AFRICA: CAR T-CELL THERAPY MARKET, BY END USER, 2022-2029 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 215)
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CAR T-CELL THERAPY MARKET
TABLE 235 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
12.3 REVENUE ANALYSIS
FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN CAR T-CELL THERAPY MARKET (2021-2023)
12.4 MARKET SHARE ANALYSIS
FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CAR T-CELL THERAPY MARKET (2023)
TABLE 236 CAR T-CELL THERAPY MARKET: DEGREE OF COMPETITION
12.4.1 RANKING OF KEY MARKET PLAYERS
FIGURE 37 RANKING OF KEY PLAYERS IN CAR T-CELL THERAPY MARKET, 2023
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 38 CAR T-CELL THERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5.1 Company footprint
FIGURE 39 CAR T-CELL MARKET: COMPANY FOOTPRINT
12.5.5.2 Product footprint
TABLE 237 CAR T-CELL THERAPY MARKET: PRODUCT FOOTPRINT
12.5.5.3 Target footprint
TABLE 238 CAR T-CELL THERAPY MARKET: TARGET FOOTPRINT
12.5.5.4 Indication footprint
TABLE 239 CAR T-CELL THERAPY MARKET: INDICATION FOOTPRINT
12.5.5.5 Region footprint
TABLE 240 CAR T-CELL THERAPY MARKET: REGION FOOTPRINT
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 40 CAR T-CELL THERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
TABLE 241 CAR T-CELL THERAPY MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
TABLE 242 CAR T-CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
12.7 VALUATION & FINANCIAL METRICS
12.7.1 FINANCIAL METRICS
FIGURE 41 EV/EBITDA OF KEY VENDORS
12.7.2 COMPANY VALUATION
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
12.8 BRAND/PRODUCT COMPARISON
FIGURE 43 CAR T-CELL THERAPY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES & APPROVALS
TABLE 243 CAR T-CELL THERAPY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MARCH 2024
12.9.2 DEALS
TABLE 244 CAR T-CELL THERAPY MARKET: DEALS, JANUARY 2021-MARCH 2024
12.9.3 EXPANSIONS
TABLE 245 CAR T-CELL THERAPY MARKET: EXPANSIONS, JANUARY 2021-MARCH 2024
12.9.4 OTHER DEVELOPMENTS
TABLE 246 CAR T-CELL THERAPY MARKET: OTHER DEVELOPMENTS, JANUARY 2021-MARCH 2024

13 COMPANY PROFILES (Page No. - 232)
13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 BRISTOL-MYERS SQUIBB COMPANY
TABLE 247 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
FIGURE 44 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2023)
TABLE 248 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED
TABLE 249 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS, JANUARY 2021-MAY 2024
TABLE 250 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2021-MAY 2024
13.1.2 GILEAD SCIENCES, INC.
TABLE 251 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
FIGURE 45 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2023)
TABLE 252 GILEAD SCIENCES, INC.: PRODUCTS OFFERED
TABLE 253 GILEAD SCIENCES, INC.: PRODUCT APPROVALS, JANUARY 2021-MAY 2024
TABLE 254 GILEAD SCIENCES, INC.: DEALS, JANUARY 2021-MAY 2024
TABLE 255 GILEAD SCIENCES, INC.: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2024
13.1.3 NOVARTIS AG
TABLE 256 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 46 NOVARTIS AG: COMPANY SNAPSHOT (2023)
TABLE 257 NOVARTIS AG: PRODUCTS OFFERED
TABLE 258 NOVARTIS AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−MAY 2024
TABLE 259 NOVARTIS AG: EXPANSIONS, JANUARY 2021−MAY 2024
TABLE 260 NOVARTIS AG: OTHER DEVELOPMENTS, JANUARY 2021−MAY 2024
13.1.4 JOHNSON & JOHNSON
TABLE 261 JOHNSON & JOHNSON: COMPANY OVERVIEW
FIGURE 47 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2023)
TABLE 262 JOHNSON & JOHNSON: PRODUCTS OFFERED
TABLE 263 JOHNSON & JOHNSON: PRODUCT APPROVALS, JANUARY 2021−MAY 2024
TABLE 264 JOHNSON & JOHNSON: DEALS, JANUARY 2021−MAY 2024
13.1.5 JW (CAYMAN) THERAPEUTICS CO. LTD.
TABLE 265 JW (CAYMAN) THERAPEUTICS CO. LTD.: COMPANY OVERVIEW
FIGURE 48 JW (CAYMAN) THERAPEUTICS CO. LTD.: COMPANY SNAPSHOT (2023)
TABLE 266 JW (CAYMAN) THERAPEUTICS CO. LTD.: PRODUCTS OFFERED
TABLE 267 JW (CAYMAN) THERAPEUTICS CO. LTD.: PRODUCT APPROVALS, JANUARY 2021−MAY 2024
TABLE 268 JW (CAYMAN) THERAPEUTICS CO. LTD.: DEALS, JANUARY 2021−MAY 2024
13.1.6 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT)
TABLE 269 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: COMPANY OVERVIEW
TABLE 270 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: PRODUCTS OFFERED
TABLE 271 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: DEALS, JANUARY 2021−MAY 2024
TABLE 272 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2024
13.1.7 CARSGEN THERAPEUTICS HOLDINGS LIMITED
TABLE 273 CARSGEN THERAPEUTICS HOLDINGS LIMITED: COMPANY OVERVIEW
TABLE 274 CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCTS OFFERED
TABLE 275 CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCT APPROVALS, JANUARY 2021−MAY 2024
TABLE 276 CARSGEN THERAPEUTICS HOLDINGS LIMITED: DEALS, JANUARY 2021−MAY 2024
TABLE 277 CARSGEN THERAPEUTICS HOLDINGS LIMITED: EXPANSIONS, JANUARY 2021−MAY 2024
13.1.8 IASO BIOTHERAPEUTICS
TABLE 278 IASO BIOTHERAPEUTICS: COMPANY OVERVIEW
TABLE 279 IASO BIOTHERAPEUTICS: PRODUCTS OFFERED
TABLE 280 IASO BIOTHERAPEUTICS: PRODUCT APPROVALS, JANUARY 2021−MAY 2024
TABLE 281 IASO BIOTHERAPEUTICS: DEALS, JANUARY 2021−MAY 2024
13.2 OTHER PLAYERS
13.2.1 GUANGZHOU BIO-GENE TECHNOLOGY CO., LTD (HEDY GROUP CO., LTD.)
13.2.2 CARTESIAN THERAPEUTICS, INC.
13.2.3 AUTOLUS THERAPEUTICS
13.2.4 ALLOGENE THERAPEUTICS
13.2.5 CRISPR THERAPEUTICS
13.2.6 WUGEN
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

14 APPENDIX (Page No. - 269)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS